Orphan drugs: privilege of "fictitious" additional benefit not justified

IQWiG

12 January 2022 - Drugs for orphan diseases should also go through a regular benefit assessment procedure when they enter the market. 

This is shown by a current IQWiG evaluation.

Read IQWiG press release

Michael Wonder

Posted by:

Michael Wonder